Whole Powder
Dried, ground fruiting body powder — the form used in the mild cognitive impairment and Alzheimer's disease clinical trials.
Powder
Hericium erinaceus (Bull.) Persoon — a distinctive, spine-covered tooth fungus long used in Traditional Chinese Medicine, studied for erinacine and hericenone compounds that stimulate nerve growth factor (NGF) synthesis and support nerve regeneration.
Hericium erinaceus is a curiously shaped fungus, distinguished by long, white, hanging spines rather than gills or pores, growing on dead hardwood. Also known as Yamabushitake, bearded tooth, monkey head, satyr's beard, or pom pom mushroom, it has been used for centuries in Traditional Chinese Medicine, generally as a tonic to relieve stress, anxiety and support digestive health.
Hericium erinaceus has been used by Traditional Chinese Medicine for centuries, generally as a tonic to relieve stress, anxiety and depression, and traditionally associated with digestive health and nerve regeneration.
Modern pharmacological interest began with the discovery of hericenones in the fruiting body and erinacines in the mycelium — two distinct classes of compounds capable of stimulating nerve growth factor (NGF) synthesis — and has since expanded into a substantial body of preclinical and, increasingly, human clinical research on cognition and neuroprotection.
Two distinct terpenoid classes, unique to this fungus, anchor nearly every documented neurotrophic effect: erinacines from the mycelium, hericenones from the fruiting body.
Hericium erinaceus increases expression of the Nerve Growth Factor (NGF) gene in human astrocytoma cells. [6]
Hericenones isolated from cultivated fruiting bodies demonstrate NGF-mediated neurite outgrowth via MEK/ERK and PI3K-Akt signaling pathways in PC12 cells. [2]
Extract promotes development of cerebellar cells in culture and stimulates myelin synthesis in vitro. [7]
Erinacine A protects against MPTP-induced neurotoxicity through modulation of ER stress and the apoptosis cascade. [5]
Both the fruiting body and mycelium are used, most commonly as powder or standardized dry extract.
Dried, ground fruiting body powder — the form used in the mild cognitive impairment and Alzheimer's disease clinical trials.
Powder
Concentrated dry extract, often standardized to beta-glucan or erinacine A content.
Dry Extract · Standardized
Erinacine-rich mycelium extract, the form used in the 49-week Alzheimer's disease pilot trial. [18]
Mycelium Extract
Traditional dosing and the doses used across the major clinical trials.
Documented composition of the fungus, the sole category with described components in the primary source.
Usable in nerve regeneration and reduces apoptosis of nerve cells. [1][2][3][4]
Documented neuroprotective and anti-inflammatory activity specific to neuronal tissue. [5]
Increases Nerve Growth Factor gene expression in human 1321N1 astrocytoma cells. [6]
Promotes cerebellar cell development in culture and stimulates myelin synthesis in vitro. [7]
Documented hypoglycemic effect of the extract. [8]
Protective against experimental gastric ulcer, via upregulation of HSP70 and downregulation of BAX protein. [9]
Documented in vitro anti-H. pylori activity, including via a bismuth-polysaccharide complex. [10][11]
Water- and alkali-soluble polysaccharides show both prebiotic and antioxidant activity. [12]
Broad documented potential across anticancer, immunomodulant, hypolipidemic and antioxidant activity. [13]
Improved Stroop task speed following a single dose, and a trend toward reduced subjective stress after 28 days, in healthy young adults. [16]
A 49-week randomized trial in mild Alzheimer's disease patients found improved Mini-Mental State Examination scores versus placebo. [18]
Documented uses, including one the primary source itself flags as uncertain.
The documented mechanisms behind erinacine and hericenone neurotrophic activity — this section was not developed in the primary source and is built entirely from the peer-reviewed studies below.
Extract stimulates myelin synthesis and cerebellar cell development in vitro, a mechanism distinct from but complementary to NGF induction. [7]
Erinacine A protects against MPTP-induced neurotoxicity by modulating endoplasmic reticulum stress and interrupting the apoptosis cascade. [5]
The primary source left this section undeveloped — everything below is drawn from formal toxicology studies, human trials and a documented case report.
This monograph draws on the primary botanical source plus substantial additional peer-reviewed literature, given how little the original entry covered on history, mode of action and safety — every added claim is linked to a verifiable, named source below.